编者按：第93届欧洲动脉粥样硬化学会年会（EAS 2025）即将于5月4~7日在英国格拉斯哥开启，此次会议采用现场与在线结合的模式，为全球医学专家、学者搭建交流平台。在本次会议中，药物相关日程备受瞩目，涵盖了传统药物新进展、前沿新药探索以及处于试验阶段的潜力药物。这些内容将为动脉粥样硬化的治疗提供新思路、新方向，对改善患者预后意义重大。让我们一同聚焦会议药物日程，紧跟动脉粥样硬化治疗领域的最新动态。
当地时间：2025年5月5日 星期一
在临床实践中应用新工具
Session Type：Workshop
Date：Mon, 05.05.2025
Room：William Harvey Hall
HIGH-INTENSITY STATIN VS INITIAL COMBINATION OF STATIN AND EZETIMIBE FOLLOWING A FIRST CORONARY EVENT: A NATIONWIDE POPULATION-BASED COHORT STUDY
首次冠状动脉事件后高强度他汀对比他汀与依折麦布初始联合治疗：一项全国性基于人群的队列研究
Presenter：Bertrand Cariou (France)
Lecture Time：11:50 - 12:00
动脉粥样硬化：多器官系统性病变
Session Type：Workshop
Date：Mon, 05.05.2025
Room：James Black Hall
Cardiometabolic effects of SGLT2 inhibition
SGLT2抑制剂对心脏代谢的影响
Presenter：Paola Fioretto (Italy)
Lecture Time：11:20 - 11:40
降脂治疗与血管疾病治疗新进展
Session Type：SaaG Session (E-Poster Screens)
Date：Mon, 05.05.2025
Room：Station 04
ANTIPLATELET AND ANTICOAGULANT COMPOUND (APAC) RESTRICTS THROMBOINFLAMMATION TO AMELIORATES MYOCARDIAL ISCHEMIA REPERFUSION INJURY
抗血小板及抗凝复合物（APAC）通过抑制血栓炎症改善心肌缺血再灌注损伤
Presenter：Amna Arif (Germany)
Lecture Time：13:58 - 14:05
INCLISIRAN AS MONOTHERAPY COMPARED WITH PLACEBO OR EZETIMIBE IN PATIENTS AT LOW TO BORDERLINE ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RISK: RESULTS FROM THE VICTORION-MONO RANDOMIZED CLINICAL TRIAL
VICTORION-MONO随机临床试验结果：低至临界动脉粥样硬化性心血管疾病风险患者中，英克司兰单药治疗与安慰剂或依折麦布的疗效对比
Presenter：Pam Taub (United States of America)
Lecture Time：14:05 - 14:12
PALISADE: PLOZASIRAN DECREASES THE RISK OF ACUTE PANCREATITIS (AP) AND MAY IMPROVE QUALITY OF LIFE (QOL) IN FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)
PALISADE研究：PLOZASIRAN降低家族性乳糜微粒血症综合征（FCS）患者急性胰腺炎风险并可能改善生活质量（QOL）
Presenter：Gerald F. Watts (Australia)
Lecture Time：14:12 - 14:19
LOW-DOSE OBICETRAPIB SIGNIFICANTLY INCREASES CONCENTRATIONS OF LIPOPHILIC ANTIOXIDANTS, APOE, AND S1P IN HDL SUBFRACTIONS
低剂量OBICETRAPIB显著升高高密度脂蛋白亚组分中脂溶性抗氧化剂、载脂蛋白E（ApoE）及鞘氨醇-1-磷酸（S1P）浓度
Presenter：Eric J. Niesor (Switzerland)
Lecture Time：14:19 - 14:26
新兴降脂策略：机制、临床前研究及疗效评估
Session Type：SaaG Session (E-Poster Screens)
Date：Mon, 05.05.2025
Room：Station 07
PLASMA REDUCTION OF APOLIPOPROTEIN C-III WITH OLEZARSEN LEADS TO SIGNIFICANT REDUCTIONS IN POSTPRANDIAL TRIGLYCERIDE LEVELS
OLEZARSEN降低血浆载脂蛋白C-III水平可显著减少餐后甘油三酯水平
Presenter：Nick Nurmohamed (Netherlands)
Lecture Time：13:30 - 13:37
REDUCED POSTPRANDIAL LIPID ACCUMULATION IN MONOCYTES BY OLEZARSEN ATTENUATES PRO-INFLAMMATORY CHANGES IN HYPERTRIGLYCERIDEMIC PATIENTS
OLEZARSEN减少高甘油三酯血症患者餐后单核细胞脂质积聚并缓解促炎改变
Presenter：Merel C. Peletier (Netherlands)
Lecture Time：13:37 - 13:44
TRANSITION OF PATIENTS WITH FAMILIAL CHYLOMICRONAEMIA SYNDROME FROM VOLANESORSEN TO OLEZARSEN: UPDATED INTERIM SAFETY AND PHARMACOKINETIC RESULTS
家族性乳糜微粒血症综合征患者从VOLANESORSEN转换为OLEZARSEN治疗：安全性及药代动力学中期结果更新
Presenter：Daniel Gaudet (Canada)
Lecture Time：13:44 - 13:51
OPTIMIZATION OF EPIGENETIC REGULATORS FOR EFFICIENT AND LONG-LASTING SILENCING OF PCSK9 IN NON-HUMAN PRIMATES
表观遗传调控因子高效持久沉默非人灵长类PCSK9表达的优化策略
Presenter：Shaoshuai Mao (China)
Lecture Time：13:51 - 13:58
OBICETRAPIB REDUCES ATHEROSCLEROSIS AND VASCULAR INFLAMMATION, MAINLY BY REDUCING NON-HDL CHOLESTEROL, IMPROVES LESION STABILITY AND ADDS TO THE BENEFICIAL EFFECTS OF EZETIMIBE
OBICETRAPIB通过主要降低非HDL-C减少动脉粥样硬化及血管炎症，改善斑块稳定性并增强依折麦布的获益效应
Presenter：Jose A. Inia (Netherlands)
Lecture Time：13:58 - 14:05
OBICETRAPIB ALONE AND IN COMBINATION WITH EZETIMIBE INCREASES REVERSE CHOLESTEROL TRANSPORT AND DOES NOT AFFECT VLDL PRODUCTION
OBICETRAPIB单用及联合依折麦布可增强胆固醇逆向转运且不影响VLDL生成
Presenter：Jose A. Inia (Netherlands)
Lecture Time：14:05 - 14:12
USAGE OF BEMPEDOIC ACID AND/OR ITS FIXED-DOSE COMBINATION WITH EZETIMIBE IN BELGIAN PATIENTS WITH DYSLIPIDAEMIA: BASELINE CHARACTERISTICS AND 8-WEEK FOLLOW-UP DATA FROM THE MILOS STUDY
血脂异常患者使用贝派地酸和/或其与依折麦布固定剂量复方制剂的现状：MILOS研究基线特征及8周随访数据
Presenter：Thomas Vanassche (Belgium)
Lecture Time：14:12 - 14:19
IMPACT OF BEMPEDOIC ACID ON SKELETAL MUSCLE MITOCHONDRIAL ACTIVITY IN APOE-/- MICE – A PRELIMINARY ANALYSIS.
贝派地酸对ApoE-/-小鼠骨骼肌线粒体活性的影响——初步分析
Presenter：Chiara Macchi (Italy)
Lecture Time：14:19 - 14:26
新一代降脂治疗：PCSK9抑制剂及其他新型靶点
Session Type：SaaG Session (E-Poster Screens)
Date：Mon, 05.05.2025
Room：Station 07
RISK OF ADVERSE EVENTS FOR STATINS, EZETIMIBE, BEMPEDOIC ACID, PCSK9 INHIBITORS, AND THEIR COMBINATIONS IN PATIENTS WITH DYSLIPIDEMIA: A NETWORK META-ANALYSIS
他汀类、依折麦布、贝派地酸、PCSK9抑制剂及其联合用药对血脂异常患者不良事件风险的网络Meta分析
Presenter：Sining Xie (Italy)
Lecture Time：14:35 - 14:42
REAL WORLD INSIGHTS FROM THE UNITED KINGDOM ON 8-WEEK EFFECTIVENESS OF BEMPEDOIC ACID AND/OR ITS FIXED-DOSE COMBINATION WITH EZETIMIBE IN PATIENTS WITH DYSLIPIDAEMIA
英国真实世界研究：贝派地酸单用及联合依折麦布治疗血脂异常患者的8周疗效观察
Presenter：Kausik K. Ray (United Kingdom)
Lecture Time：14:42 - 14:49
LIPID-LOWERING EFFICACY OF OBICETRAPIB: A COMPREHENSIVE SYSTEMATIC REVIEW AND META-ANALYSIS.
OBICETRAPIB降脂疗效的系统评价与Meta分析
Presenter：Juan P. Nogueira (Argentina)
Lecture Time：14:49 - 14:56
EVALUATING DYSLIPIDAEMIA TREATMENT WITH BEMPEDOIC ACID AND EZETIMIBE OVER 8 WEEKS IN THE ITALIAN COHORT OF THE MILOS OBSERVATIONAL STUDY
MILOS观察性研究意大利队列：贝派地酸联合依折麦布治疗血脂异常的8周疗效评估
Presenter：Maurizio Averna (Italy)
Lecture Time：14:56 - 15:03
PERSISTENCE AND DETERMINANTS OF THERAPY DISCONTINUATION WITH PCSK9 MONOCLONAL ANTIBODIES IN PATIENTS AT VERY HIGH CARDIOVASCULAR RISK: PERI-DYS
极高心血管风险患者PCSK9单克隆抗体治疗中断的持续性与决定因素：PERI-DYS研究
Presenter：Klaus Parhofer (Germany)
Lecture Time：15:03 - 15:10
REAL-WORLD ADHERENCE, LDL-C LOWERING EFFECT AND GOAL-ATTAINMENT OF INCLISIRAN IN BELGIAN PATIENTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: THE BE.REAL REGISTRY
比利时动脉粥样硬化性心血管疾病患者INCLISIRAN用药依从性、LDL-C降低效果及目标达成率：BE.REAL注册登记研究
Presenter：Fabian Demeure (Belgium)
Lecture Time：15:10 - 15:17
REAL-WORLD PROSPECTIVE DATA FROM AUSTRIA ON BEMPEDOIC ACID AND/OR ITS FIXED-DOSE COMBINATION WITH EZETIMIBE FOR THE TREATMENT OF DYSLIPIDAEMIA
奥地利真实世界前瞻性数据：贝派地酸单用及联合依折麦布治疗血脂异常的疗效分析
Presenter：Thomas Stulnig (Austria)
Lecture Time：15:17 - 15:24
EFFICACY AND SAFETY OF AZD0780, AN ORAL SMALL MOLECULE PCSK9 INHIBITOR FOR TREATMENT OF HYPERCHOLESTEROLEMIA: RESULTS FROM A PH2B RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL
口服小分子PCSK9抑制剂AZD0780治疗高胆固醇血症的疗效与安全性：Ⅱb期随机安慰剂对照临床试验结果
Presenter：Per Johanson (Sweden)
Lecture Time：15:24 - 15:31
Late Breaker Session: 基础医学
Session Type：Late Breaker
Date：Mon, 05.05.2025
Room：William Harvey Hall
SPATIAL PROTEOMICS OF THE HUMAN ATHEROSCLEROTIC MICROENVIRONMENT REVEALS HETEROGENEITY IN INTRA-PLAQUE PROTEOMES AND EXTRACELLULAR MATRIX REMODELING
人类动脉粥样硬化微环境空间蛋白组学揭示斑块内蛋白组异质性及细胞外基质重塑
Presenter：Luke Gamon (Denmark)
Lecture Time：15:45 - 16:00
POTENT, DURABLE, AND SAFE LDLC REDUCTION IN NON-HUMAN PRIMATES WITH A NOVEL CRISPR-BASED EPIGENETIC SILENCER AT THERAPEUTICALLY RELEVANT DOSES
新型CRISPR表观遗传沉默剂在非人灵长类中实现强效、持久且安全的LDL-C降低：治疗剂量下的疗效评估
Presenter：Aarif Khakoo (United States of America)
Lecture Time：16:00 - 16:15
DOXORUBICIN PROMOTES ATHEROSCLEROSIS IN AN APOLIPOPROTEIN E-DEFICIENT MOUSE MODEL, POTENTIALLY ASSOCIATED WITH SERPINA3N
阿霉素通过SERPINA3N相关机制加剧载脂蛋白E缺陷小鼠动脉粥样硬化病变
Presenter：Sander Eens (Belgium)
Lecture Time：16:30 - 16:45
EXAMINING THE EFFECTS OF RITUXIMAB ON THE BCR REPERTOIRE FOLLOWING ANTERIOR ST ELEVATION MYOCARDIAL INFARCTION.
前壁ST段抬高型心肌梗死患者B细胞受体库对利妥昔单抗治疗的响应特征分析
Presenter：James W. O'Brien (United Kingdom)
Lecture Time：16:45 - 17:00
当地时间：2025年5月6日 星期二
家族性高胆固醇血症（FH）与高胆固醇血症：新兴疗法与临床新视角
Session Type：SaaG Session (E-Poster Screens)
Date：Tue, 06.05.2025
Room：Station 04
BASELINE CHARACTERISTICS AND RESPONSE TO EVINACUMAB IN WOMEN AND MEN WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN THE ELIPSE OLE STUDY
ELIPSE OLE研究：纯合子家族性高胆固醇血症患者基线特征及对Evinacumab治疗的性别差异反应
Presenter：Diane Brisson (Canada)
Lecture Time：13:58 - 14:05
ASSOCIATION BETWEEN STATIN ADHERENCE AND ARTERIAL STIFFNESS IN YOUNG ADULTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: A CROSS-SECTIONAL STUDY
家族性高胆固醇血症青年患者他汀类药物依从性与动脉僵硬度关联的横断面研究
Presenter：Sibbeliene E. Van Den Bosch (Netherlands)
Lecture Time：14:05 - 14:12
EFFICACY OF LERODALCIBEP, A THIRD GENERATION PCSK9 INHIBITOR, ACCORDING TO FH GENOTYPE IN SUBJECTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
第三代PCSK9抑制剂Lerodalcibep治疗杂合子家族性高胆固醇血症的疗效差异：基于FH基因型的亚组分析
Presenter：Frederick J. Raal (South Africa)
Lecture Time：14:19 - 14:26
心血管风险管理领域的新兴疗法与基因新洞察
Session Type：SaaG Session (E-Poster Screens)
Date：Tue, 06.05.2025
Room：Station 08
TREATMENT STRATEGIES AND LDL CHOLESTEROL TARGET ATTAINMENT IN PATIENTS WITH STATIN INTOLERANCE: INSIGHTS FROM THE MULTICENTRE STATIN INTOLERANCE REGISTRY
他汀类药物不耐受患者的治疗策略及低密度脂蛋白胆固醇目标达成情况：来自多中心他汀类药物不耐受登记研究的洞察
Presenter：Julius L. Katzmann (Germany)
Lecture Time：13:37 - 13:44
A PHASE 1 TRIAL OF UDP-003, A THERAPEUTIC TO REVERSE ATHEROSCLEROSIS BY THE SPECIFIC REMOVAL OF 7-KETOCHOLESTEROL
UDP-003Ⅰ期临床试验：一种通过特异性清除7-酮胆固醇逆转动脉粥样硬化的治疗药物
Presenter：Daniel M. Clemens (United States of America)
Lecture Time：13:44 - 13:51
COMMON GENETIC VARIANTS IN GIP AND GIPR AS PROXIES FOR BODY WEIGHT REDUCTION VIA GIP RECEPTOR-TARGETING AND RISK OF CARDIOVASCULAR DISEASE
GIP和GIPR常见遗传变异作为GIP受体靶向治疗减轻体重的替代指标及与心血管疾病风险的关系
Presenter：Frida Emanuelsson (Denmark)
Lecture Time：13:51 - 13:58
当地时间：2025年5月7日 星期三
Late Breaker Session: 临床医学
Session Type：Late Breaker
Date：Wed, 07.05.2025
Room：William Harvey Hall
ZODASIRAN (ARO-ANG3), AN INVESTIGATIONAL RNAI THERAPEUTIC, DEMONSTRATES PROFOUND AND DURABLE REDUCTIONS IN LDL-CHOLESTEROL, APOLIPOPROTEIN B, AND ANGPTL3 IN PATIENTS WITH HOFH; GATEWAY FINAL RESULTS
ZODASIRAN（ARO-ANG3，研究性RNAi治疗药物）可显著且持久降低纯合子家族性高胆固醇血症患者的LDL-C、载脂蛋白B及ANGPTL3水平：GATEWAY研究最终结果
Presenter：Frederick J. Raal (South Africa)
Lecture Time：11:00 - 11:15
LIPOPROTEIN(A) AND RECURRENT ATHEROSCLEROTIC CARDIOVASCULAR DISEASE EVENTS BY SEX AND RACE/ETHNICITY AND USE OF LDL CHOLESTEROL LOWERING THERAPY: A COHORT STUDY FROM THE US FAMILY HEART DATABASE
脂蛋白(a)与复发性动脉粥样硬化性心血管疾病事件的关联：基于美国家族心脏数据库的队列研究，分析性别、种族/民族差异及降LDL-C治疗的影响
Presenter：Borge G. Nordestgaard (Denmark)
Lecture Time：11:15 - 11:30
A NOVEL ANGPTL4 INHIBITORY ANTIBODY SAFELY LOWERS PLASMA TRIGLYCERIDES AND REMNANT CHOLESTEROL IN HUMANS
新型ANGPTL4抑制性抗体在人体中安全降低血浆甘油三酯及残余胆固醇
Presenter：Ethan J. Weiss (United States of America)
Lecture Time：11:30 - 11:45
FIXED-DOSE COMBINATION OF OBICETRAPIB AND EZETIMIBE FOR LDL-C REDUCTION: A PHASE 3 RANDOMIZED TRIAL
OBICETRAPIB联合依折麦布固定剂量复方制剂降低LDL-C的疗效与安全性：Ⅲ期随机对照试验
Presenter：Steven E. Nissen (United States of America)
Lecture Time：12:00 - 12:15
SAFETY AND EFFICACY OF OBICETRAPIB IN PATIENTS AT HIGH CARDIOVASCULAR RISK
OBICETRAPIB治疗高心血管风险患者的安全性及有效性评估
Presenter：Stephen J. Nicholls (Australia)
Lecture Time：12:15 - 12:30
我要留言